PL3813942T3 - Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerek - Google Patents
Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerekInfo
- Publication number
- PL3813942T3 PL3813942T3 PL19796519.7T PL19796519T PL3813942T3 PL 3813942 T3 PL3813942 T3 PL 3813942T3 PL 19796519 T PL19796519 T PL 19796519T PL 3813942 T3 PL3813942 T3 PL 3813942T3
- Authority
- PL
- Poland
- Prior art keywords
- centhaquin
- treating
- salt
- composition
- kidney function
- Prior art date
Links
- UJNWGFBJUHIJKK-UHFFFAOYSA-N 2-[2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]quinoline Chemical compound CC1=CC=CC(N2CCN(CCC=3N=C4C=CC=CC4=CC=3)CC2)=C1 UJNWGFBJUHIJKK-UHFFFAOYSA-N 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 230000007423 decrease Effects 0.000 title 1
- 230000003907 kidney function Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666675P | 2018-05-03 | 2018-05-03 | |
| IN201841019588 | 2018-05-25 | ||
| PCT/US2019/030652 WO2019213558A1 (en) | 2018-05-03 | 2019-05-03 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3813942T3 true PL3813942T3 (pl) | 2024-07-22 |
Family
ID=68386694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19796519.7T PL3813942T3 (pl) | 2018-05-03 | 2019-05-03 | Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerek |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12629406B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3813942B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7458032B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112469474A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019262612B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020022395A2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2978951T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3813942T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019213558A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2424529T3 (pl) | 2009-04-30 | 2017-06-30 | Midwestern University | Nowe postępowania terapeutyczne z zastosowaniem centakwiny |
| CN112469474A (zh) | 2018-05-03 | 2021-03-09 | 美国中西部大学 | 出血和centhaquin引起的复苏后内皮素受体的变化 |
| WO2022240964A1 (en) * | 2021-05-11 | 2022-11-17 | Pharmazz, Inc. | Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ards) in corona virus disease (covid-19) |
| US20240207356A1 (en) * | 2022-12-26 | 2024-06-27 | Pharmazz, Inc. | Composition and method for wound healing and repair of damaged nerves |
| US20240382461A1 (en) * | 2023-05-15 | 2024-11-21 | Pharmazz, Inc. | Pharmaceutical composition and method for prevention and treatment of hearing loss |
| IN202411028038A (cg-RX-API-DMAC7.html) * | 2024-04-04 | 2025-05-23 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954987A (en) | 1972-12-22 | 1976-05-04 | Sandoz, Inc. | 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock |
| DE2421382A1 (de) | 1974-05-03 | 1975-11-20 | Council Scient Ind Res | 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge |
| JPS604186B2 (ja) | 1974-05-13 | 1985-02-01 | カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ | 1―m―トリル―4―(B―2―キノリエチル)―ピペラジンの製造法 |
| US3983121A (en) | 1974-07-01 | 1976-09-28 | Council Of Scientific And Industrial Research | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof |
| DE2557784C2 (de) | 1975-12-22 | 1986-04-17 | Hoechst Ag, 6230 Frankfurt | Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate |
| US4761417A (en) | 1982-05-14 | 1988-08-02 | Maroko Peter R | Compounds, compositions and method of treatments for improving circulatory performance |
| EP0126327A1 (en) | 1983-04-26 | 1984-11-28 | Frank J. Macri | Norepinephrine potentiated pharmaceutical composition, ophthalmic solution and kit containing the same |
| US5055470A (en) | 1989-06-01 | 1991-10-08 | Bristol-Myers Squibb Co. | Method of treatment of ischemia in brain |
| JPH0597891A (ja) * | 1991-04-24 | 1993-04-20 | Banyu Pharmaceut Co Ltd | 血管弛緩ペプチド類 |
| US5922681A (en) | 1992-09-14 | 1999-07-13 | Warner-Lambert Company | Endothelin antagonists |
| US20040063719A1 (en) | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6369114B1 (en) | 1999-11-30 | 2002-04-09 | Institute Of Critical Care Medicine | Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation |
| GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| SE0004455D0 (sv) | 2000-12-01 | 2000-12-01 | Milos Pekny | Method for neuron regeneration in the central nervous system |
| US6573285B2 (en) | 2000-12-21 | 2003-06-03 | Bristol-Myers Squibb Co. | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030232787A1 (en) | 2001-05-08 | 2003-12-18 | Dooley David James | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| US20030104976A1 (en) | 2001-07-23 | 2003-06-05 | Gudarz Davar | Analgesic methods using endothelin receptor ligands |
| US7030082B2 (en) | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US20070066568A1 (en) * | 2005-08-31 | 2007-03-22 | Dalton James T | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
| US7351692B2 (en) | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| CN1729012B (zh) | 2002-10-24 | 2013-05-22 | 伊利诺伊大学评议会 | 治疗实体瘤的组合物 |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US20050009847A1 (en) | 2002-11-20 | 2005-01-13 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
| US7906140B2 (en) * | 2004-06-17 | 2011-03-15 | Virun, Inc. | Compositions for mucosal delivery of agents |
| WO2008043102A2 (en) | 2006-10-06 | 2008-04-10 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide compositions |
| JP4976412B2 (ja) * | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
| JP2009530407A (ja) | 2006-03-23 | 2009-08-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト |
| BRPI0809171A2 (pt) | 2007-04-02 | 2014-09-16 | Auspex Pharmaceuticals Inc | "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina" |
| CA2683857A1 (en) | 2007-04-10 | 2008-10-16 | Auspex Pharmaceuticals, Inc. | Substituted deuterium enriched thiophenes for the treatment of hypertension |
| PL2182977T3 (pl) | 2007-08-21 | 2017-01-31 | Midwestern University | Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B |
| US20100189802A1 (en) | 2007-08-21 | 2010-07-29 | Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation | Method for treatment of vascular hyperpermeability |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| CN101374259B (zh) | 2007-08-22 | 2012-08-08 | 华为技术有限公司 | 实现多媒体彩铃和多媒体彩像业务的方法和装置 |
| EP2165706A1 (en) | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
| PL2424530T3 (pl) | 2009-04-30 | 2016-07-29 | Univ Midwestern | Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej |
| PL2424529T3 (pl) * | 2009-04-30 | 2017-06-30 | Midwestern University | Nowe postępowania terapeutyczne z zastosowaniem centakwiny |
| WO2011159854A1 (en) | 2010-06-17 | 2011-12-22 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of ccr2 |
| US20130296331A1 (en) | 2010-11-26 | 2013-11-07 | Technion Research And Development Foundation Ltd. | Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury |
| KR101418941B1 (ko) | 2011-04-04 | 2014-07-15 | 서울대학교병원 | 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물 |
| US20150250782A1 (en) | 2012-08-31 | 2015-09-10 | Pharmazz, Inc. | Methods and Compositions for Hypotensive Resuscitation |
| EP3019242B1 (en) * | 2013-07-08 | 2020-08-19 | Midwestern University | Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist |
| CN112469474A (zh) | 2018-05-03 | 2021-03-09 | 美国中西部大学 | 出血和centhaquin引起的复苏后内皮素受体的变化 |
| JP2025149692A (ja) | 2024-03-26 | 2025-10-08 | ローム株式会社 | 無線通信回路 |
| JP2026006612A (ja) | 2024-06-28 | 2026-01-16 | 多摩川精機株式会社 | 温度検出体固定用溝付き絶縁キャップ、回転電機の温度検出体固定構造、温度検出体固定済み回転電機、回転電機の温度検出体固定方法、および回転電機製造装置 |
-
2019
- 2019-05-03 CN CN201980038669.0A patent/CN112469474A/zh active Pending
- 2019-05-03 PL PL19796519.7T patent/PL3813942T3/pl unknown
- 2019-05-03 AU AU2019262612A patent/AU2019262612B2/en active Active
- 2019-05-03 BR BR112020022395-6A patent/BR112020022395A2/pt not_active Application Discontinuation
- 2019-05-03 US US17/052,473 patent/US12629406B2/en active Active
- 2019-05-03 EP EP19796519.7A patent/EP3813942B1/en active Active
- 2019-05-03 JP JP2020561786A patent/JP7458032B2/ja active Active
- 2019-05-03 EP EP24163271.0A patent/EP4364811A3/en active Pending
- 2019-05-03 WO PCT/US2019/030652 patent/WO2019213558A1/en not_active Ceased
- 2019-05-03 ES ES19796519T patent/ES2978951T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3099128A1 (en) | 2019-11-07 |
| US20210169978A1 (en) | 2021-06-10 |
| EP3813942A4 (en) | 2022-01-19 |
| EP3813942B1 (en) | 2024-04-17 |
| CN112469474A (zh) | 2021-03-09 |
| BR112020022395A2 (pt) | 2021-04-13 |
| AU2019262612A1 (en) | 2020-11-26 |
| EP4364811A3 (en) | 2024-07-10 |
| EP4364811A2 (en) | 2024-05-08 |
| ES2978951T3 (es) | 2024-09-23 |
| WO2019213558A1 (en) | 2019-11-07 |
| EP3813942A1 (en) | 2021-05-05 |
| US12629406B2 (en) | 2026-05-19 |
| JP2021523125A (ja) | 2021-09-02 |
| AU2019262612B2 (en) | 2025-04-03 |
| JP7458032B2 (ja) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277551A (en) | Tri-specific binding molecules against cancer and their uses | |
| SG11202104356VA (en) | Bt1718 for use in treating cancer | |
| IL327200A (en) | CD47-binding factors and their uses in the treatment of diseases | |
| SG11202106605VA (en) | Compounds that participate in cooperative binding and uses thereof | |
| SG11202105747XA (en) | Csf1r inhibitors for use in treating cancer | |
| GB201802201D0 (en) | Binding agents | |
| SG11202009933WA (en) | Bcl-2 INHIBITORS | |
| PL3704108T3 (pl) | Inhibitor irak4 w połączeniu z inhibitorem bcl-2 do stosowania w leczeniu nowotworu złośliwego | |
| EP3997667A4 (en) | MEMORY IN ANIMATED AGENTS | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| GB201804094D0 (en) | ERBB3 Binding agents | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| IL286949A (en) | Mesitantan for use in the treatment of portopulmonary hypertension | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL276914A (en) | CSF1R binding factors | |
| PL3826679T3 (pl) | Związki indukujące ABCA1 do stosowania w leczeniu chorób nerek | |
| SG11202100269VA (en) | Compounds for use in the treatment of fascioliasis | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| ZA202004991B (en) | New spirooxathiolanone compounds, their preparation method as well as their use in perfume-making and aromatics industry | |
| SG11202103435RA (en) | Agent for reducing the phosphate concentration in wastewater | |
| GB201809458D0 (en) | Salt form | |
| GB201809460D0 (en) | Salt form | |
| PT3813832T (pt) | Compostos para utilização na prevenção ou tratamento de cancro | |
| HK40052012A (en) | Usp19 inhibitors for use in therapy | |
| GB201912159D0 (en) | A composition for use in treating fibromyalgia |